📊 RNXT Key Takeaways
Is RNXT a Good Investment? Thesis Analysis
RenovoRx shows exceptional early-stage revenue growth (+2511% YoY) and strong gross margins (70.9%), indicating successful initial commercialization of its pharmaceutical product. However, the company faces critical near-term challenges: it is burning ~$11M annually with only ~$7M in cash on hand, providing less than one year of runway, combined with operating losses of $12.5M and net losses of $11.2M with no clear path to profitability.
Why Buy RNXT? Key Strengths
- Exceptional revenue growth of 2511.6% YoY demonstrates strong market traction and commercialization success
- Healthy gross margin of 70.9% indicates the product economics and unit business model are fundamentally sound
- Strong liquidity position with 4.02x current ratio and minimal debt (0.00x debt/to-equity), reducing financial distress risk
RNXT Investment Risks to Consider
- Critical cash runway: $7M in cash with $11M annual burn rate provides less than 9 months of operations; company will need dilutive financing or must achieve dramatic revenue acceleration
- Deeply negative net income (-$11.2M) and operating income (-$12.5M) indicate operations far from breakeven; no clear inflection point to profitability
- Early-stage pharmaceutical company with execution risk; continued revenue growth is not guaranteed and requires successful market adoption
Key Metrics to Watch
- Quarterly revenue run-rate and sustainability of growth beyond initial commercialization phase
- Monthly cash burn rate and cash runway; any additional financing announcements
- Gross margin stability and operating expense control as company scales
RNXT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.02x current ratio provides a solid financial cushion.
RNXT Profitability Ratios
RNXT vs Healthcare Sector
How RenovoRx, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RNXT Overvalued or Undervalued?
Based on fundamental analysis, RenovoRx, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RNXT Balance Sheet & Liquidity
RNXT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: RenovoRx, Inc.'s revenue has grown significantly by 2,512% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.40 indicates the company is currently unprofitable.
RNXT Growth Metrics (YoY)
RNXT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $266.0K | -$1.1M | $-0.08 |
| Q2 2025 | $422.0K | -$1.1M | $-0.08 |
| Q1 2025 | $197.0K | -$1.1M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RNXT Capital Allocation
RNXT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for RenovoRx, Inc. (CIK: 0001574094)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNXT
What is the AI rating for RNXT?
RenovoRx, Inc. (RNXT) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNXT's key strengths?
Claude: Exceptional revenue growth of 2511.6% YoY demonstrates strong market traction and commercialization success. Healthy gross margin of 70.9% indicates the product economics and unit business model are fundamentally sound.
What are the risks of investing in RNXT?
Claude: Critical cash runway: $7M in cash with $11M annual burn rate provides less than 9 months of operations; company will need dilutive financing or must achieve dramatic revenue acceleration. Deeply negative net income (-$11.2M) and operating income (-$12.5M) indicate operations far from breakeven; no clear inflection point to profitability.
What is RNXT's revenue and growth?
RenovoRx, Inc. reported revenue of $1.1M.
Does RNXT pay dividends?
RenovoRx, Inc. does not currently pay dividends.
Where can I find RNXT SEC filings?
Official SEC filings for RenovoRx, Inc. (CIK: 0001574094) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNXT's EPS?
RenovoRx, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNXT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, RenovoRx, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNXT stock overvalued or undervalued?
Valuation metrics for RNXT: ROE of -206.0% (sector avg: 15%), net margin of -994.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNXT stock in 2026?
Our dual AI analysis gives RenovoRx, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNXT's free cash flow?
RenovoRx, Inc.'s operating cash flow is $-11.0M, with capital expenditures of $2.0K. FCF margin is -977.3%.
How does RNXT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -994.5% (avg: 12%), ROE -206.0% (avg: 15%), current ratio 4.02 (avg: 2).